Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13642116 | 0.82 | EPHX2 (0.39) | EPHX2KDM1AKMT2A | |
| SCHEMBL3229882 | 0.68 | EPHX2 (0.51) | EPHX2SMYD3 | |
| SCHEMBL3229891 | 0.68 | EPHX2 (0.51) | EPHX2SMYD3 | |
| SCHEMBL3539009 | 0.68 | EPHX2 (0.51) | EPHX2SMYD3 | |
| SCHEMBL1963074 | 0.67 | MEN1 (0.37) | EPHX2KDM1AKMT2A | |
| SCHEMBL23610675 | 0.65 | EPHX2 (0.45) | EPHX2KMT2ASMYD3LMNABLM | |
| SCHEMBL23610674 | 0.65 | EPHX2 (0.45) | EPHX2KMT2ASMYD3LMNABLM | |
| SCHEMBL2377885 | 0.65 | GAA (0.43) | KDM1AKMT2A | |
| SCHEMBL2362043 | 0.64 | — | — | |
| SCHEMBL1966542 | 0.63 | EPHX2 (0.33) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859605-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8853281-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-10-07 | — | — | US | disclosed |
| US-8815809-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-08-26 | — | — | US | disclosed |
| EP-2509956-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2014-07-23 | — | — | EP | disclosed |
| US-20120309673-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2012-12-06 | — | — | US | disclosed |
| US-20120283305-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2012-11-08 | — | — | US | disclosed |
| EP-2509956-A1 | CYSTEINE PROTEASE INHIBITORS | Medivir UK Ltd (GB) | 2012-10-17 | — | — | EP | disclosed |
| US-20110312964-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2011-12-22 | — | — | US | disclosed |
| EP-2358692-A1 | CYSTEINE PROTEASE INHIBITORS | Medivir UK Ltd (GB) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011070539-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010070615-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312964-A1 | CYSTEINE PROTEASE INHIBITORS | CTSS, CTSB, CTSV | EPHX2 341/4885KDM1A 3238/4885KMT2A 2827/4885 |
| US-20120309673-A1 | CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTRB1 | EPHX2 240/4885KDM1A 2997/4885KMT2A 2690/4885 |
| US-20120283305-A1 | CYSTEINE PROTEASE INHIBITORS | CTSS, CTSB, CTRB1 | EPHX2 496/4885KDM1A 3045/4885KMT2A 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.